Opinion|Videos|August 2, 2023

IMerge Trial: Key Efficacy Outcomes

Author(s)Abdulraheem Yacoub, MD

Following the 2023 ASCO Annual Meeting, Abdulraheem Yacoub, MD, reviews key data updates from the IMerge trial investigating imetelstat in patients with lower-risk MDS.

Episodes in this series

Elias Jabbour, MD, an expert on myelodysplastic syndrome

EP. 1 Overview of Myelodysplastic Syndrome

Elias Jabbour, MD, an expert on myelodysplastic syndrome

EP. 2 Clinical Insights on Treating Myelodysplastic Syndrome

Abdulraheem Yacoub, MD, an expert on myelodysplastic syndrome

EP. 3 IMerge Trial: Key Efficacy Outcomes

Abdulraheem Yacoub, MD, an expert on myelodysplastic syndrome

EP. 4 Data Updates From the IMerge Trial

Eytan M. Stein, MD, an expert on myelodysplastic syndrome

EP. 5 Follow-Up Efficacy Data of Imetelstat in Lower-Risk MDS

Eytan M. Stein, MD, an expert on myelodysplastic syndrome

EP. 6 Evolving Treatment Landscape in Lower-Risk MDS

EP. 7 Safety Outcomes for Imetelstat in Lower-Risk MDS

Amer Zeidan, MBBS, MHS, an expert on myelodysplastic syndrome

EP. 8 Updates in the Management of Lower-Risk MDS

Amer Zeidan, MBBS, MHS, an expert on myelodysplastic syndrome

EP. 9 Recent Updates in Lower-Risk MDS

Yazan Madanat, MD, an expert on myelodysplastic syndromes

EP. 10 Updates in Lower-Risk MDS: Imetelstat

Yazan Madanat, MD, an expert on MDS

EP. 11 Key Updates in Lower-Risk MDS

Newsletter

Stay up to date on practice-changing data in community practice.

Related to this article

Adding Quality of Life to Treatment Goals in Immune Thrombocytopenia

October 8th, 2026

Adding Quality of Life to Treatment Goals in Immune Thrombocytopenia

During a roundtable event, Amit R. Mehta, MD, and participants discussed treatment selection for a patient with immune thrombocytopenia whose quality of life is impaired even as her platelet count recovers.

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

2026 AACR Report Highlights Advances and New Directions in Cancer Treatment

ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types

Retlirafusp Alfa Improves Overall Survival in Phase 3 Trial of HER2– Gastric Cancer

Dr Beck on the Practical Realities of Subcutaneous Oncology Drug Delivery

Invikafusp Alfa Receives Second FDA Fast Track Designation for TMB-High Solid Tumors